Abstract
Nitric oxide synthase (NOS) is a dimeric enzyme that catalyses the production of nitric oxide (NO) in the human body. The nitric oxide has been identified as the most interesting and vital mediators for normal and pathological processes, including the regulation of blood pressure, neurotransmission, and macrophage defence system, but the over production of it can be toxic, hence their inhibitors are desired. In this article, the various isoforms of NOS and their roles are described and a detail of the development of their inhibitors has been presented. The inhibitors studied include aminopyridines, iminopiperidines, N-phenylamidines, benzoxazolones, isothioureas, oxazepanes, thiazepanes, diazepanes, 4,5-disubstituted-1,3-oxazolidin-2-imine derivatives, thiazolidines, pyrazoles, pyrazolines, and some others.
Keywords: Nitric oxide synthase (NOS), Nitric oxide synthase inhibitors, aminopyridines, iminopiperidines, N-phenylamidines, benzoxazolones, isothioureas, oxazepanes, thiazepanes, diazepanes, 4, 5-disubstituted-1, 3-oxazolidin-2-imine derivatives, thiazolidines, pyrazoles, pyrazolines
Current Enzyme Inhibition
Title:Advances in Design and Development of Inhibitors of Nitric Oxide Synthases
Volume: 9 Issue: 2
Author(s): Harish Kumar, Satya P. Gupta, Anees A. Siddiqui and Vijay Kumar
Affiliation:
Keywords: Nitric oxide synthase (NOS), Nitric oxide synthase inhibitors, aminopyridines, iminopiperidines, N-phenylamidines, benzoxazolones, isothioureas, oxazepanes, thiazepanes, diazepanes, 4, 5-disubstituted-1, 3-oxazolidin-2-imine derivatives, thiazolidines, pyrazoles, pyrazolines
Abstract: Nitric oxide synthase (NOS) is a dimeric enzyme that catalyses the production of nitric oxide (NO) in the human body. The nitric oxide has been identified as the most interesting and vital mediators for normal and pathological processes, including the regulation of blood pressure, neurotransmission, and macrophage defence system, but the over production of it can be toxic, hence their inhibitors are desired. In this article, the various isoforms of NOS and their roles are described and a detail of the development of their inhibitors has been presented. The inhibitors studied include aminopyridines, iminopiperidines, N-phenylamidines, benzoxazolones, isothioureas, oxazepanes, thiazepanes, diazepanes, 4,5-disubstituted-1,3-oxazolidin-2-imine derivatives, thiazolidines, pyrazoles, pyrazolines, and some others.
Export Options
About this article
Cite this article as:
Kumar Harish, Gupta P. Satya, Siddiqui A. Anees and Kumar Vijay, Advances in Design and Development of Inhibitors of Nitric Oxide Synthases, Current Enzyme Inhibition 2013; 9 (2) . https://dx.doi.org/10.2174/1573408011309020005
DOI https://dx.doi.org/10.2174/1573408011309020005 |
Print ISSN 1573-4080 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6662 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Combination Secondary Prevention Therapies in Vascular Diseases
Vascular Disease Prevention (Discontinued) The Association between Serum Asymmetric Dimethylarginine and Coronary Atherosclerotic Plaque in an Asymptomatic Population
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) New Drugs, Therapeutic Strategies, and Future Direction for the Treatment of Pulmonary Arterial Hypertension
Current Medicinal Chemistry The Differential Diagnostic Value of the Callosal Angle and Evans Index in Mild Cognitive Impairment and Alzheimer's Disease
Current Medical Imaging Attenuation of Diabetes-induced Cardiac and Subcellular Defects by Sulphur-containing Amino Acids
Current Medicinal Chemistry Drug-Induced Anemia and Other Red Cell Disorders: A Guide in the Age of Polypharmacy
Current Clinical Pharmacology Can the Electrophysiological Action of Rosiglitazone Explain its Cardiac Side Effects?
Current Medicinal Chemistry Sleep Apnea and Atrial Fibrillation; 2012 Update
Current Cardiology Reviews Current Pharmacological Treatment of Pulmonary Arterial Hypertension
Current Clinical Pharmacology Circadian Variation of Cardiovascular Events and Morning Blood Pressure Surge
Vascular Disease Prevention (Discontinued) Editorial (Hot Topic: Introduction to the Special Issue: Relevance of Endocrine and Metabolic Disorders in Heart Failure: From Pathophysiology to Therapeutic Approach)
Endocrine, Metabolic & Immune Disorders - Drug Targets Pro- and Anti-Arrhythmic Effects of Anti-Inflammatory Drugs
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Molecular Targets for Promoting Wound Healing in Diabetes
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) The Impact of Dietary Habits and Nutritional Deficiencies in Urban African Patients Living with Heart Failure in Soweto, South Africa – A Review
Endocrine, Metabolic & Immune Disorders - Drug Targets Transport Mechanisms at the Blood-Cerebrospinal-Fluid Barrier: Role of Megalin (LRP2)
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) The Association of Chemotherapy and Radiotherapy: Breast Cancer
Current Drug Therapy Advanced Nanomedicines for the Treatment and Diagnosis of Myocardial Infarction and Heart Failure
Current Drug Targets Age-related Changes in Pharmacodynamics: Focus on Drugs Acting on Central Nervous and Cardiovascular Systems
Current Drug Metabolism Augmentation of Creatine in the Heart
Mini-Reviews in Medicinal Chemistry Treating Arterial Stiffness in Young and Elderly Patients with the Metabolic Syndrome
Current Pharmaceutical Design